化疗会对身体健康产生不利影响，而炎症可能与身体健康的变化有关。我们评估了全身炎症与身体健康变化的关联。在一项对 580 名 I-III 期乳腺癌患者进行的前瞻性研究中，我们评估了免疫细胞计数、中性粒细胞:淋巴细胞比率 (NLR)、淋巴细胞:单核细胞比率 (LMR) ，以及化疗前 7 天内的血小板：淋巴细胞比值 (PLR)（化疗前）。使用癌症治疗功能评估：化疗前和化疗后 1 个月和 6 个月的一般身体健康分量表 (FACT-PWB) 评估身体健康。具有临床意义的身体健康下降被确定为 FACT-PWB 较化疗前水平下降超过 1 个百分点，无弹性被定义为化疗后下降且未恢复到化疗前 FACT 1 个百分点以内-化疗后 6 个月的 PWB。多变量逻辑回归检查了炎症与身体健康变化之间的关联，并根据社会人口统计学和临床​​特征进行了调整。59% (310/529) 和 36% (178/501) 的参与者在治疗后身体健康状况下降分别为化疗后6个月和化疗后6个月。百分之五十 (147/294) 缺乏弹性。与高 NLR 和 PLR 的患者相比，低 NLR 和 PLR 与化疗后 6 个月身体健康下降的几率分别高 1.78 (P = .01) 和 1.66 (P = .02) 倍。与高 NLR 和 PLR 的患者相比，低 NLR 和 PLR 与化疗后 6 个月无弹性的几率分别高 1.92 (P = .02) 和 2.09 (P = 0.01) 倍。与化疗引起的身体健康变化相关，独立于社会人口统计学和临床​​危险因素。© 作者 2024。由牛津大学出版社出版。

Chemotherapy adversely affects physical well-being and inflammation may be related to changes in physical well-being. We evaluated the association of systemic inflammation with changes in physical well-being.In a prospective study of 580 patients with stages I-III breast cancer we assessed immune cell counts, neutrophil:lymphocyte ratio (NLR), lymphocyte:monocyte ratio (LMR), and platelet:lymphocyte ratio (PLR) within 7 days before chemotherapy (pre-chemotherapy). Physical well-being was assessed using the Functional Assessment of Cancer Therapy: General-Physical Well-being subscale (FACT-PWB) pre-chemotherapy and 1 month and 6 months post-chemotherapy. Clinically meaningful decline in physical well-being was determined as decreasing FACT-PWB by more than one point from pre-chemotherapy level, and non-resilience defined as having decline post-chemotherapy and not returning to within one-point of pre-chemotherapy FACT-PWB by 6 months post-chemotherapy. Multivariable logistic regressions examined the association between inflammation and changes in physical well-being, adjusting for sociodemographic and clinical characteristics.Fifty-nine percent (310/529) and 36% (178/501) of participants had physical well-being decline post-chemotherapy and 6 months post-chemotherapy, respectively. Fifty percent (147/294) were non-resilient. Low NLR and PLR were associated with 1.78 (P = .01) and 1.66 (P = .02) fold greater odds of having a decline in physical well-being 6 months post-chemotherapy compared to those with high NLR and PLR, respectively. Low NLR and PLR were associated with 1.92 (P = .02) and 2.09 (P = 0.01) fold greater odds of being non-resilient 6 months post-chemotherapy compared to those with high NLR and PLR, respectively.Low NLR and PLR were associated with chemotherapy-induced changes in physical well-being independent of sociodemographic and clinical risk factors.© The Author(s) 2024. Published by Oxford University Press.